119 related articles for article (PubMed ID: 16047355)
1. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Cancer; 2005 Sep; 104(6):1312-21. PubMed ID: 16047355
[TBL] [Abstract][Full Text] [Related]
2. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Endocr Relat Cancer; 2005 Dec; 12(4):999-1009. PubMed ID: 16322338
[TBL] [Abstract][Full Text] [Related]
3. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Eur J Cancer; 2005 Aug; 41(12):1824-30. PubMed ID: 16051478
[TBL] [Abstract][Full Text] [Related]
4. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Keller G; Schally AV; Nagy A; Halmos G; Baker B; Engel JB
Cancer; 2005 Nov; 104(10):2266-74. PubMed ID: 16211544
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
Kahán Z; Nagy A; Schally AV; Hebert F; Sun B; Groot K; Halmos G
Int J Cancer; 1999 Aug; 82(4):592-8. PubMed ID: 10404076
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
Plonowski A; Schally AV; Koppan M; Nagy A; Arencibia JM; Csernus B; Halmos G
Cancer; 2001 Sep; 92(5):1168-76. PubMed ID: 11571730
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
[TBL] [Abstract][Full Text] [Related]
9. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Buchholz S; Keller G; Schally AV; Halmos G; Hohla F; Heinrich E; Koester F; Baker B; Engel JB
Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10403-10407. PubMed ID: 16801542
[TBL] [Abstract][Full Text] [Related]
10. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
[TBL] [Abstract][Full Text] [Related]
13. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
[TBL] [Abstract][Full Text] [Related]
14. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts.
Kolfschoten GM; Hulscher TM; Pinedo HM; Boven E
Br J Cancer; 2000 Oct; 83(7):921-7. PubMed ID: 10970695
[TBL] [Abstract][Full Text] [Related]
16. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160.
Mishima M; Yano T; Jimbo H; Yano N; Morita Y; Yoshikawa H; Schally AV; Taketani Y
Am J Obstet Gynecol; 1999 Sep; 181(3):583-90. PubMed ID: 10486467
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Nagy A; Schally AV; Halmos G; Armatis P; Cai RZ; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1794-9. PubMed ID: 9465096
[TBL] [Abstract][Full Text] [Related]
20. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Szepeshazi K; Schally AV; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Clin Cancer Res; 2001 Sep; 7(9):2854-61. PubMed ID: 11555603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
